Device type · LBZ
Enzyme Immunoassay, Quinidine
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
LBZ
Clinical Toxicology
Device class
Class II
FDA decisions since 2015
0
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Enzyme Immunoassay, Quinidine
- Product code
- LBZ
- Device class
- Class II
- Review panel
- Clinical Toxicology
- Regulation
- 21 CFR 862.3320
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for LBZ
Latest FDA decisions
No 510(k), De Novo or PMA decisions for this product code since 2015.
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Siemens Healthcare Diagnostics, Inc.
Z-2975-2026 · Started Jul 13, 2026 · Posted by FDA Aug 17, 2026
Reason given: Due to unacceptable precision performance exhibited in certain lots of the Emit 2000 Quinidine Assay, which may lead to erroneously elevated quinidine measurements, creating risk of sub-optimal patient treatment, including potential life-threatening cardiac arrhythmias or inadequate antimalarial therapy.
Cause as FDA categorized it: Unknown/Undetermined by firm
- Beckman Coulter, Emit 2000 Quinidine Assay REF: OSR4Q229 Contents: R1: 2 x 23 mL;R2 2x13 mLOpen, Classified
Siemens Healthcare Diagnostics, Inc.
Z-2976-2026 · Started Jul 13, 2026 · Posted by FDA Aug 17, 2026
Reason given: Due to unacceptable precision performance exhibited in certain lots of the Emit 2000 Quinidine Assay, which may lead to erroneously elevated quinidine measurements, creating risk of sub-optimal patient treatment, including potential life-threatening cardiac arrhythmias or inadequate antimalarial therapy.
Cause as FDA categorized it: Unknown/Undetermined by firm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.